E. Cipriano, Lauren S. Zaric, Gregory Holodniy, Mark Bendavid, Eran K. Owens, Douglas L. Brandeau, Margaret Base case outcomes and incremental cost-effectiveness ratios for non-dominated strategies in a representative city of 2.5 million individuals age 15–59 years, with 1.2% of the population IDU, and 6.5% and 35% prevalence of HIV and HCV among IDU, respectively.<sup>*</sup> <p>HIV – human immunodeficiency virus; HCV – hepatitis C virus; LYs – life years; QALYs – quality-adjusted life-years; ICER – incremental cost-effectiveness ratio; IDU – injection drug user.</p>*<p>Outcomes for all strategies considered are shown in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0045176#pone.0045176.s006" target="_blank">Table S3</a>.</p>**<p>Frequencies considered were: Upon entry to ORT; “Annual” = Upon entry to ORT and annually while in ORT; “6 months” = Upon entry to ORT and every 6 months while in ORT; “3 months” = Upon entry to ORT and every 3 months while in ORT.</p>***<p>“Dominated” indicates that the strategy costs more and provides fewer benefits than another strategy or a combination of two strategies.</p>****<p>This strategy consists of baseline case detection rates in the IDU and non-IDU populations and no screening targeted to individuals in ORT.</p> outcomes;incremental;cost-effectiveness;ratios;non-dominated;strategies;individuals;prevalence;hiv;hcv 2012-09-18
    https://plos.figshare.com/articles/dataset/_Base_case_outcomes_and_incremental_cost_effectiveness_ratios_for_non_dominated_strategies_in_a_representative_city_of_2_5_million_individuals_age_15_59_years_with_1_2_of_the_population_IDU_and_6_5_and_35_prevalence_of_HIV_and_HCV_among_IDU_respectively_/246342
10.1371/journal.pone.0045176.t002